<a href="https://www.fiercebiotech.com/biotech/ethyreal-bio-manifests-101m-pack-biotechs-gunning-amgens-tepezza" hreflang="en">Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza</a>
Ethyreal Bio has emerged from stealth with $101 million in funding to advance its anti-TSHR antibody, ETHY-001, aimed at treating thyroid eye disease and Graves' disease, positioning itself against Amgen's Tepezza. The company plans to initiate a first-in-human trial this year, joining a competitive landscape of biotech firms targeting similar conditions.
Ethyreal Bio's emergence from stealth with $101 million in funding to advance its anti-TSHR antibody for thyroid eye disease and Graves' disease signals a significant competitive move in the biotech space targeting Amgen's Tepezza. With a first-in-human trial for ETHY-001 scheduled this year, this presents an investment opportunity in a biotech company positioned to address unmet needs in overlapping conditions, potentially offering a dual-treatment approach that current therapies lack. Keep an eye on Ethyreal's progress and upcoming data presentations for deeper insights into their clinical strategy and innovation.